schliessen

Filtern

 

Bibliotheken

The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.

BACKGROUNDIt has been shown that induction high-dose interferon alpha-2b (IFN-alpha-2b) followed by maintenance therapy improves recurrence-free survival in adults with high-risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnosed pediatr... Full description

Journal Title: Cancer February 15, 2005, Vol.103(4), pp.780-787
Main Author: Navid, Fariba
Other Authors: Furman, Wayne L , Fleming, Martin , Rao, Bhaskar N , Kovach, Sandra , Billups, Catherine A , Cain, Alvida M , Amonette, Rex , Jenkins, Jesse J , Pappo, Alberto S
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X
Link: http://search.proquest.com/docview/67434573/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest67434573
title: The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
format: Article
creator:
  • Navid, Fariba
  • Furman, Wayne L
  • Fleming, Martin
  • Rao, Bhaskar N
  • Kovach, Sandra
  • Billups, Catherine A
  • Cain, Alvida M
  • Amonette, Rex
  • Jenkins, Jesse J
  • Pappo, Alberto S
subjects:
  • Adolescent–Adverse Effects
  • Antineoplastic Agents–Adverse Effects
  • Chemotherapy, Adjuvant–Drug Therapy
  • Child–Mortality
  • Child, Preschool–Surgery
  • Feasibility Studies–Drug Therapy
  • Humans–Mortality
  • Infant–Surgery
  • Interferon-Alpha–Surgery
  • Lymph Node Excision–Surgery
  • Melanoma–Surgery
  • Recombinant Proteins–Surgery
  • Sentinel Lymph Node Biopsy–Surgery
  • Skin Neoplasms–Surgery
  • Survival–Surgery
  • Abridged
  • Antineoplastic Agents
  • Interferon-Alpha
  • Recombinant Proteins
  • Interferon Alfa-2b
ispartof: Cancer, February 15, 2005, Vol.103(4), pp.780-787
description: BACKGROUNDIt has been shown that induction high-dose interferon alpha-2b (IFN-alpha-2b) followed by maintenance therapy improves recurrence-free survival in adults with high-risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnosed pediatric patients with Stage III melanoma involving regional lymph nodes. METHODSFifteen patients age
language: eng
source:
identifier: ISSN: 0008-543X
fulltext: fulltext
issn:
  • 0008543X
  • 0008-543X
url: Link


@attributes
ID1128472318
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid67434573
sourceidproquest
recordidTN_proquest67434573
sourcesystemOther
pqid67434573
galeid133346774
display
typearticle
titleThe feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
creatorNavid, Fariba ; Furman, Wayne L ; Fleming, Martin ; Rao, Bhaskar N ; Kovach, Sandra ; Billups, Catherine A ; Cain, Alvida M ; Amonette, Rex ; Jenkins, Jesse J ; Pappo, Alberto S
contributorNavid, Fariba (correspondence author) ; Navid, Fariba (record owner)
ispartofCancer, February 15, 2005, Vol.103(4), pp.780-787
identifierISSN: 0008-543X
subjectAdolescent–Adverse Effects ; Antineoplastic Agents–Adverse Effects ; Chemotherapy, Adjuvant–Drug Therapy ; Child–Mortality ; Child, Preschool–Surgery ; Feasibility Studies–Drug Therapy ; Humans–Mortality ; Infant–Surgery ; Interferon-Alpha–Surgery ; Lymph Node Excision–Surgery ; Melanoma–Surgery ; Recombinant Proteins–Surgery ; Sentinel Lymph Node Biopsy–Surgery ; Skin Neoplasms–Surgery ; Survival–Surgery ; Abridged ; Antineoplastic Agents ; Interferon-Alpha ; Recombinant Proteins ; Interferon Alfa-2b
descriptionBACKGROUNDIt has been shown that induction high-dose interferon alpha-2b (IFN-alpha-2b) followed by maintenance therapy improves recurrence-free survival in adults with high-risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnosed pediatric patients with Stage III melanoma involving regional lymph nodes. METHODSFifteen patients age
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/67434573/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Navid, Fariba
1Furman, Wayne L
2Fleming, Martin
3Rao, Bhaskar N
4Kovach, Sandra
5Billups, Catherine A
6Cain, Alvida M
7Amonette, Rex
8Jenkins, Jesse J
9Pappo, Alberto S
titleThe feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
descriptionBACKGROUNDIt has been shown that induction high-dose interferon alpha-2b (IFN-alpha-2b) followed by maintenance therapy improves recurrence-free survival in adults with high-risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnosed pediatric patients with Stage III melanoma involving regional lymph nodes. METHODSFifteen patients age
subject
0Adolescent–Adverse Effects
1Antineoplastic Agents–Adverse Effects
2Chemotherapy, Adjuvant–Drug Therapy
3Child–Mortality
4Child, Preschool–Surgery
5Feasibility Studies–Drug Therapy
6Humans–Mortality
7Infant–Surgery
8Interferon-Alpha–Surgery
9Lymph Node Excision–Surgery
10Melanoma–Surgery
11Recombinant Proteins–Surgery
12Sentinel Lymph Node Biopsy–Surgery
13Skin Neoplasms–Surgery
14Survival–Surgery
15Abridged
16Antineoplastic Agents
17Interferon-Alpha
18Recombinant Proteins
19Interferon Alfa-2b
general
0English
1MEDLINE (ProQuest)
2ProQuest Biological Science Collection
3ProQuest Environmental Science Collection
4ProQuest Natural Science Collection
5ProQuest SciTech Collection
6Agricultural & Environmental Science Database
7Biological Science Database
8Natural Science Collection
9SciTech Premium Collection
10Health Research Premium Collection
11Health Research Premium Collection (Alumni edition)
sourceidproquest
recordidproquest67434573
issn
00008543X
10008-543X
rsrctypearticle
creationdate2005
addtitleCancer
searchscope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
scope
01007489
11007527
21007944
310000004
410000006
510000038
610000043
710000050
810000120
910000159
1010000198
1110000200
1210000209
1310000217
1410000234
1510000238
1610000253
1710000260
1810000270
1910000271
2010000302
21proquest
lsr43
01007489false
11007527false
21007944false
310000004false
410000006false
510000038false
610000043false
710000050false
810000120false
910000159false
1010000198false
1110000200false
1210000209false
1310000217false
1410000234false
1510000238false
1610000253false
1710000260false
1810000270false
1910000271false
2010000302false
contributorNavid, Fariba
startdate20050215
enddate20050215
citationpf 780 pt 787 vol 103 issue 4
lsr30VSR-Enriched:[doi, galeid, pqid, eissn]
sort
titleThe feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
authorNavid, Fariba ; Furman, Wayne L ; Fleming, Martin ; Rao, Bhaskar N ; Kovach, Sandra ; Billups, Catherine A ; Cain, Alvida M ; Amonette, Rex ; Jenkins, Jesse J ; Pappo, Alberto S
creationdate20050215
lso0120050215
facets
frbrgroupid4971585385777645038
frbrtype5
newrecords20181218
languageeng
creationdate2005
topic
0Adolescent–Adverse Effects
1Antineoplastic Agents–Adverse Effects
2Chemotherapy, Adjuvant–Drug Therapy
3Child–Mortality
4Child, Preschool–Surgery
5Feasibility Studies–Drug Therapy
6Humans–Mortality
7Infant–Surgery
8Interferon-Alpha–Surgery
9Lymph Node Excision–Surgery
10Melanoma–Surgery
11Recombinant Proteins–Surgery
12Sentinel Lymph Node Biopsy–Surgery
13Skin Neoplasms–Surgery
14Survival–Surgery
15Abridged
16Antineoplastic Agents
17Interferon-Alpha
18Recombinant Proteins
19Interferon Alfa-2b
collection
0MEDLINE (ProQuest)
1ProQuest Biological Science Collection
2ProQuest Environmental Science Collection
3ProQuest Natural Science Collection
4ProQuest SciTech Collection
5Agricultural & Environmental Science Database
6Biological Science Database
7Natural Science Collection
8SciTech Premium Collection
9Health Research Premium Collection
10Health Research Premium Collection (Alumni edition)
prefilterarticles
rsrctypearticles
creatorcontrib
0Navid, Fariba
1Furman, Wayne L
2Fleming, Martin
3Rao, Bhaskar N
4Kovach, Sandra
5Billups, Catherine A
6Cain, Alvida M
7Amonette, Rex
8Jenkins, Jesse J
9Pappo, Alberto S
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Navid
1Furman
2Fleming
3Rao
4Kovach
5Billups
6Cain
7Amonette
8Jenkins
9Pappo
aufirst
0Fariba
1Wayne L
2Martin
3Bhaskar N
4Sandra
5Catherine A
6Alvida M
7Rex
8Jesse J
9Alberto S
au
0Navid, Fariba
1Furman, Wayne L
2Fleming, Martin
3Rao, Bhaskar N
4Kovach, Sandra
5Billups, Catherine A
6Cain, Alvida M
7Amonette, Rex
8Jenkins, Jesse J
9Pappo, Alberto S
addauNavid, Fariba
atitleThe feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
jtitleCancer
risdate20050215
volume103
issue4
spage780
epage787
pages780-787
issn0008-543X
formatjournal
genrearticle
ristypeJOUR
abstractBACKGROUNDIt has been shown that induction high-dose interferon alpha-2b (IFN-alpha-2b) followed by maintenance therapy improves recurrence-free survival in adults with high-risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnosed pediatric patients with Stage III melanoma involving regional lymph nodes. METHODSFifteen patients age
urlhttp://search.proquest.com/docview/67434573/
doi10.1002/cncr.20860
eissn10970142
date2005-02-15